BCG treatment elevated the proportion of activated CD69+Granzyme-B+ and reduced exhausted PD-1+ TIM-1+CD8+ tumor-infiltrating lymphocytes in control mice (Figure 7F–I; gating scheme in Supplementary Figure S4). The gene discussed is CD8A; the disease is neoplasm.